Targeting cancer cell protein granules to improve treatment
Therapeutic targeting of RTK protein granules in cancer
['FUNDING_CAREER'] · SLOAN-KETTERING INST CAN RESEARCH · NIH-11087566
This study is looking at how certain proteins in cancer cells form clusters that help the cancer grow, and it's working on new treatments that can target these clusters to help patients with advanced cancers who haven't responded to regular therapies.
Quick facts
| Phase | ['FUNDING_CAREER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | SLOAN-KETTERING INST CAN RESEARCH (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-11087566 on ClinicalTrials.gov |
What this research studies
This research investigates how certain proteins in cancer cells, specifically RTK fusion oncoproteins, form granules that play a crucial role in cancer progression. The project aims to develop new therapies that specifically target these granules to disrupt their function and improve treatment outcomes for patients with advanced cancers. The approach includes using mouse models and advanced microscopy techniques to study these protein structures and their effects on cancer signaling. By understanding the biology behind these granules, the research seeks to create more effective treatments for patients who have become resistant to standard therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults with advanced cancers driven by RTK fusion oncoproteins.
Not a fit: Patients with early-stage cancers or those not driven by RTK fusion oncoproteins may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly improve treatment options for patients with advanced cancer.
How similar studies have performed: Other research has shown promise in targeting similar oncogenic signaling pathways, indicating potential for success in this approach.
Where this research is happening
NEW YORK, UNITED STATES
- SLOAN-KETTERING INST CAN RESEARCH — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: TULPULE, ASMIN — SLOAN-KETTERING INST CAN RESEARCH
- Study coordinator: TULPULE, ASMIN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Advanced Cancer